Literature DB >> 23530950

Ticlopidine-associated ADAMTS13 activity deficient thrombotic thrombocytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions (SONAR).

Charles L Bennett, Sony Jacob, Brianne L Dunn, Peter Georgantopoulos, X Long Zheng, Hau C Kwaan, June M McKoy, Jametta S Magwood, Zaina P Qureshi, Nicholas Bandarenko, Jeffrey L Winters, Thomas J Raife, Patricia M Carey, Ravindra Sarode, Joseph E Kiss, Constance Danielson, Thomas L Ortel, William F Clark, Richard J Ablin, Gail Rock, Masanori Matsumoto, Yoshihiro Fujimura.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23530950      PMCID： PMC3804577          DOI： 10.1111/bjh.12303

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Thrombotic thrombocytopenic purpura associated with ticlopidine in the setting of coronary artery stents and stroke prevention.

Authors:  C L Bennett; C J Davidson; D W Raisch; P D Weinberg; R H Bennett; M D Feldman
Journal:  Arch Intern Med       Date:  1999-11-22

2.  Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; L Rice; R Sarode; T W Chow; J L Moake
Journal:  Ann Intern Med       Date:  2000-05-16       Impact factor: 25.391

3.  Upshaw-Schulman syndrome revisited: a concept of congenital thrombotic thrombocytopenic purpura.

Authors:  S Kinoshita; A Yoshioka; Y D Park; H Ishizashi; M Konno; M Funato; T Matsui; K Titani; H Yagi; M Matsumoto; Y Fujimura
Journal:  Int J Hematol       Date:  2001-07       Impact factor: 2.490

4.  Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting.

Authors:  S R Steinhubl; W A Tan; J M Foody; E J Topol
Journal:  JAMA       Date:  1999-03-03       Impact factor: 56.272

5.  Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.

Authors:  H M Tsai; E C Lian
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

6.  von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.

Authors:  M Furlan; R Robles; M Galbusera; G Remuzzi; P A Kyrle; B Brenner; M Krause; I Scharrer; V Aumann; U Mittler; M Solenthaler; B Lämmle
Journal:  N Engl J Med       Date:  1998-11-26       Impact factor: 91.245

7.  Registry of 919 patients with thrombotic microangiopathies across Japan: database of Nara Medical University during 1998-2008.

Authors:  Yoshihiro Fujimura; Masanori Matsumoto
Journal:  Intern Med       Date:  2010-01-01       Impact factor: 1.271

Review 8.  Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).

Authors:  Sony Jacob; Brianne L Dunn; Zaina P Qureshi; Nicholas Bandarenko; Hau C Kwaan; Dilip K Pandey; June M McKoy; Sara E Barnato; Jeffrey L Winters; John F Cursio; Ivy Weiss; Thomas J Raife; Patricia M Carey; Ravindra Sarode; Joseph E Kiss; Constance Danielson; Thomas L Ortel; William F Clark; Gail Rock; Masanori Matsumoto; Yoshihiro Fujimura; X Long Zheng; Hao Chen; Fei Chen; John M Armstrong; Dennis W Raisch; Charles L Bennett
Journal:  Semin Thromb Hemost       Date:  2012-10-30       Impact factor: 4.180

9.  Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.

Authors:  M Furlan; R Robles; B Lämmle
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113
  9 in total
  7 in total

Review 1.  Thrombotic thrombocytopenic purpura: pathogenesis, diagnosis and potential novel therapeutics.

Authors:  M Saha; J K McDaniel; X L Zheng
Journal:  J Thromb Haemost       Date:  2017-07-27       Impact factor: 5.824

2.  The Differential Diagnosis and Treatment of Thrombotic Microangiopathies.

Authors:  Martin Bommer; Manuela Wölfle-Guter; Stephan Bohl; Florian Kuchenbauer
Journal:  Dtsch Arztebl Int       Date:  2018-05-11       Impact factor: 5.594

Review 3.  Thrombotic Microangiopathy and the Kidney.

Authors:  Vicky Brocklebank; Katrina M Wood; David Kavanagh
Journal:  Clin J Am Soc Nephrol       Date:  2017-10-17       Impact factor: 8.237

Review 4.  Relevance of ADAMTS13 to liver transplantation and surgery.

Authors:  Saiho Ko; Hisanao Chisuwa; Masanori Matsumoto; Yoshihiro Fujimura; Eiji Okano; Yoshiyuki Nakajima
Journal:  World J Hepatol       Date:  2015-07-08

Review 5.  Diagnosis and treatment of thrombotic microangiopathy.

Authors:  Gemma L Thompson; David Kavanagh
Journal:  Int J Lab Hematol       Date:  2022-09       Impact factor: 3.450

Review 6.  Dual role of Endoplasmic Reticulum Stress-Mediated Unfolded Protein Response Signaling Pathway in Carcinogenesis.

Authors:  Natalia Siwecka; Wioletta Rozpędek; Dariusz Pytel; Adam Wawrzynkiewicz; Adam Dziki; Łukasz Dziki; J Alan Diehl; Ireneusz Majsterek
Journal:  Int J Mol Sci       Date:  2019-09-05       Impact factor: 5.923

Review 7.  Snakebite Associated Thrombotic Microangiopathy and Recommendations for Clinical Practice.

Authors:  Tina Noutsos; Bart J Currie; Eranga S Wijewickrama; Geoffrey K Isbister
Journal:  Toxins (Basel)       Date:  2022-01-14       Impact factor: 4.546
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.